IXHL earnings analysis
What we found in IXHL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Incannex Healthcare reported no revenue for Q3 2026, maintaining a 100% decrease compared to the previous year. The company incurred a net loss of $4.4 million this quarter, a 7% increase in losses compared to the same quarter last year. Significant cash inflow was noted from financing activities, totaling $72.8 million, largely due to the March 2026 offering.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No Revenue Generation
- The company reported zero revenue both for the quarter and the year-to-date period, continuing the trend from prior periods.
- Increased Net Loss
- Net loss for Q3 2026 was $4.4 million, a 7% increase from $4.1 million in the same quarter last year.
- R&D Expense Decrease
- Research and development expenses decreased by $2.4 million (88%) over the prior quarter, reflecting completion of specific clinical trials.
- Amortized Stock-Based Compensation Rises
- General and administrative expenses rose by $1.5 million (459%) in Q3 2026, largely due to higher stock-based payment expenses.
- Significant Cash Position
- Cash and cash equivalents increased to $74.5 million, up $59.4 million from $15.0 million as of June 30, 2025.
- Strong Financing Activities
- Net cash provided by financing activities for the nine months reached $72.8 million, significantly higher than $11.8 million for the same period last year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Operating Losses
- The company has posted net losses continuously, with accumulated losses reaching $174.4 million as of March 31, 2026.
- Lack of Revenue Generation Pathway
- No path to revenue generation is projected without regulatory approval of drug candidates, which remains uncertain.
- Regulatory and Clinical Development Risks
- Future operational success is highly dependent on passing numerous regulatory requirements affecting drug development.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.79
What they said about what is next.
Management did not provide specific financial guidance in this report.
The filing reads worse than the one before it.
What came before.
- 10-Q · February 13, 2026
- Incannex reported no revenue for the quarter (Revenue from customers $0) and a quarterly net loss of $(6,521) (three months ended December 31, 2025) vs $(5,894) prior-year. Cash increased materially to $68,900 (as of…
- 10-Q · November 14, 2025
- Incannex reported Q1 (three months ended September 30, 2025) revenue of $0 and a net loss of $(6,407), producing EPS of $(0.02) versus prior-year EPS of $(0.29). The company completed a large share issuance that…
- 10-Q · May 15, 2025
- Incannex Healthcare reported a Q3 net loss of $3.968 million (EPS $(0.20)) versus a loss of $6.031 million (EPS $(0.38)) in the prior-year quarter, driven by lower operating expenses and non-cash gains on warrants. The…
- 10-Q · November 14, 2024
- Incannex Healthcare's Q4 2024 results reflected a significant decline in earnings with a reported net loss of $5,420,000 compared to a loss of $726,000 in Q4 2023. Revenue for the quarter stood at $12,000, marking a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IXHL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever